Tag archief: English Only

IFF Collaborates with Aryballe on “Digital Nose”

NEW YORK–(BUSINESS WIRE)– International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), established an industry-exclusive collaboration with Aryballe, a pioneer in digital olfaction technology based...

NTT Communications Expands Global IP Network with New Point-of-Presence in Toronto, Canada

New PoP Will Serve One of the Fastest Growing Technology Hubs in North America NEW YORK–(BUSINESS WIRE)– NTT Communications Corporation (NTT Com), the global data...

Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

FOSTER CITY, Calif. & SEOUL, Korea–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into...

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

Artificial Intelligence (AI)-powered applications will help predict how individual patients will respond to immunotherapies in advance of treatment Partnership will enable identification of appropriate patients...

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) INGELHEIM, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Boehringer Ingelheim and Dicerna Pharmaceuticals...

Axway Recognized as a Strong Performer in Independent Report on Strategic iPaaS And Hybrid Integration Platforms

Axway listed among “15 Providers That Matter Most” in iPaaS and Hybrid Integration PHOENIX–(BUSINESS WIRE)– Axway (Paris:AXW) (Euronext: AXW.PA) the leader in cloud enabled integration,...

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Boehringer Ingelheim Enhances Central Nervous System Disease Pipeline Vanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets NASHVILLE, Tenn. & INGELHEIM, Germany–(BUSINESS WIRE)– Boehringer...

Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies

Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide Science 37’s technology enables patients to remotely participate in clinical...

Athora Completes Acquisition of Generali Belgium

PEMBROKE, Bermuda–(BUSINESS WIRE)– Athora Holding Ltd. (together with its subsidiaries, “Athora”) today announced that it has completed the acquisition (“Acquisition”) of Generali Belgium SA /...

Arch Insurance Europe Completes Acquisition of the UK Commercial Lines Business of The Ardonagh Group

LONDON–(BUSINESS WIRE)– Arch Insurance Europe (“Arch”) has completed the acquisition of the UK Commercial Lines business owned by The Ardonagh Group and part of its...

ABB: Santa Claus Village goes digital

ZURICH–(BUSINESS WIRE)– High above the Arctic Circle, in Rovaniemi, Finland, you’ll find the Santa Claus Village, complete with glistening snow and Northern Lights, as well...

Thales and Gemalto Are Granted Regulatory Clearances by the Australian and Mexican Competition Authorities

–(BUSINESS WIRE)– Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

FOSTER CITY, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)– Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an...

Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal

LONDON–(BUSINESS WIRE)– – If accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, eligible patients could have access to these...

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– – Companies to Develop Highly Specific Inhibitors of Local TGFβ Activation – Gilead Sciences, Inc. (NASDAQ: GILD) and...